Endocrine Testing Market Report 2025

This Endocrine Testing market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The endocrine testing market size has grown strongly in recent years. It will grow from $2.55 billion in 2024 to $2.8 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to discovery of hormones and endocrine pathways, diagnostic test standardization, public health initiatives, and patient advocacy and empowerment.

The endocrine testing market size is expected to see strong growth in the next few years. It will grow to $4.01 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to growing prevalence of endocrine disorders, increased defense spending, aging population, awareness and early diagnosis, and increased awareness. Major trends in the forecast period include advancements in biomarker detection, integration of omics technologies, artificial intelligence and machine learning, quality assurance and standardization, and collaborative research and translational medicine.

The increasing prevalence of diabetes is expected to drive the growth of the endocrine testing market. Diabetes is a group of diseases characterized by high blood sugar (glucose) levels, and its prevalence is rising due to factors such as poor dietary habits, sedentary lifestyles, genetic factors, and an aging population. Endocrine testing, including tests like hemoglobin A1c, fasting plasma glucose, and C-peptide, is essential in diagnosing diabetes, monitoring glucose levels, and evaluating insulin production and sensitivity. For example, in June 2024, the National Health Service (NHS) reported a significant increase in diabetes cases among individuals under 40, with the number rising from 173,166 in 2022 to 216,440 in 2023. This surge indicates a concerning trend in diabetes prevalence among younger populations. As a result, the growing prevalence of diabetes is fueling the demand for endocrine testing solutions.

Key players in the endocrine testing market are focusing on developing point-of-care testing solutions to enhance accessibility and efficiency in diagnosing endocrine disorders. Point-of-care testing enables rapid results, aiding in prompt diagnosis and management of conditions such as heart failure in patients displaying symptoms such as shortness of breath and fatigue. For example, in April 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced a point-of-care NT-proBNP test in India. This test is specifically tailored for screening diabetes patients at risk of cardiovascular diseases such as heart failure (HF), facilitating early detection and intervention. It empowers clinicians to identify high-risk T2D patients promptly and initiate timely treatment discussions, ultimately leading to improved outcomes and patient well-being.

In October 2022, Tolmar, a US-based pharmaceutical company, acquired Jatenzo from Clarus Therapeutics, although the financial details remain undisclosed. This acquisition aligns with Tolmar's focus on pediatric endocrinology and men's health, augmenting their portfolio of specialty pharmaceutical products. Clarus Therapeutics, a US-based pharmaceutical company, specializes in developing and commercializing therapies for individuals with endocrine disorders.

Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.

North America was the largest region in the endocrine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endocrine testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Endocrine testing involves the diagnostic assessment of hormone levels within the body, typically conducted through blood, urine, or saliva analyses, to evaluate the function of the endocrine system. These tests play a vital role in diagnosing a range of endocrine disorders, such as diabetes, thyroid disorders, adrenal insufficiency, and pituitary gland disorders, enabling healthcare providers to formulate appropriate treatment and management plans for affected patients.

The primary types of endocrine testing encompass various assessments including the estradiol (E2) test, follicle-stimulating hormone (FSH) test, human chorionic gonadotropin (HCG) hormone test, luteinizing hormone (LH) test, dehydroepiandrosterone sulfate (DHEAS) test, progesterone test, testosterone test, thyroid-stimulating hormone (TSH) test, prolactin test, among others. For instance, the Estradiol (E2) Test involves a blood test to measure estradiol levels in the body. These tests utilize diverse technologies such as tandem mass spectrometry, immunoassays, monoclonal and polyclonal antibody technologies, sensor technology, clinical chemistry, among others, and are commonly conducted in hospitals, clinical laboratories, diagnostic centers, and similar healthcare facilities.

The endocrine testing market research report is one of a series of new reports that provides endocrine testing market statistics, including endocrine testing industry global market size, regional shares, competitors with a endocrine testing market share, detailed endocrine testing market segments, market trends and opportunities, and any further data you may need to thrive in the endocrine testing industry. This endocrine testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endocrine testing market consists of revenues earned by entities by providing services such as hormone level testing, thyroid function testing, diabetes testing, adrenal function testing, reproductive hormone testing, pituitary function testing, and bone metabolism testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The endocrine testing market also includes sales of assay kits, analyzers, point-of-care testing devices, reagents, software solutions, quality control materials, and calibrators and controls. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.